Publications by authors named "David Mitcheson"

Claim this Profile
E
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Sender Herschorn, Christopher R Chapple, Paul Abrams, Salvador Arlandis, David Mitcheson

BJU Int· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Marcus J Drake, Scott MacDiarmid, Christopher R Chapple, Adil Esen, Stavros Athanasiou, David Mitcheson

Int J Clin Pract· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Marcus J Drake, Christopher Chapple, Ahmet A Esen, Stavros Athanasiou, Javier Cambronero, David Mitcheson

Eur Urol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Christopher R Chapple, Steven A Kaplan, David Mitcheson, Mary Beth Blauwet, Moses Huang

Int J Urol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
Victor W Nitti, Steven Rosenberg, David H Mitcheson, Weizhong He, Allam Fakhoury

J Urol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Christopher R Chapple, Steven A Kaplan, David Mitcheson, Jiri Klecka, Jana Cummings

Eur Urol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Solifenacin on Overactive Bladder Symptoms, Symptom Bother, and Other Patient-Reported Outcomes in Subjects With or Without Incontinence: A Post Hoc Analysis of Data From VIBRANT.
Michael D Vardy, H David Mitcheson, Terri-Ann Samuels, Sergio Forero-Schwanhaeuser, Weizhong He

Female Pelvic Med Reconstr Surg· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis